Northfield Blood Substitute Rejected by FDA
Northfield Labs (NFLD) late Thursday said the Food and Drug Administration refused to approve the human blood substitute, Polyheme, for use in trauma patients suffering from severe blood loss.
The FDA's rejection of Polyheme was widely expected because the blood substitute failed its pivotal clinical trial during which serious concerns were raised about the product's safety.
Northfield released excerpts of the FDA's letter, which stated the Polyheme pivotal trial, "... did not meet the pre-specified primary efficacy endpoint," and that "based on the totality of the data in the application, FDA has determined that the data submitted do not support the proposed indication."
The FDA also noted that "the safety data of all controlled studies reveal that the administration of PolyHeme places the patients at a higher risk of significant adverse events."Northfield was trying to win a race to get the first human blood substitute approved, a race that other companies like Biopure (BPUR) and Baxter (BAX) have failed previously. It's been more than two years since Northfield first announced the failure of the phase III Polyheme study, but recall that the death rate for trauma patients treated with Polyheme was more than 13% compared with a death rate of just under 10% for patients treated with saline and blood. Scarier was the study's safety data, which went against Polyheme in every way measured. Patients treated with Polyheme reported more serious adverse events, more heart attacks and greater risks to the kidneys than the control patients. Northfield said Thursday it was evaluating the FDA response and considering the company's options. Northfield is almost out of money. Northfield shares closed Thursday at 50 cents.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV